(2S,3S)-2-methylpyrrolidine-3-carboxylic acid | 294875-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (2S,3S)-2-methylpyrrolidine-3-carboxylic acid
• CAS: 294875-04-0
• 化学式: C₆H₁₁NO₂
• 分子量: 129.159
• InChiKey: SGNKGPSXXFQUHT-WHFBIAKZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  benzyl cis-(+/-)-1-benzyl-2-methylpyrrolidine-3-carboxylate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以88%的产率得到(2S,3S)-2-methylpyrrolidine-3-carboxylic acid
  参考文献：
  名称：

  AN IMPROVED SYNTHESIS OF ENANTIOPURE β-AMINO ACIDS

  摘要：

  An improved method for the preparation of both the enantiopure beta -amino acids is presented. The diastereomer benzyl beta -amino esters, obtained by stereoselective reduction of beta -enamino esters, were separated and hydrogenolyzed to the free enantiopure beta -amino acids.

  DOI：

  10.1081/scc-100105666

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2016046530A1

  公开（公告）日：2016-03-31

  The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein.

  本发明涉及新型化合物和制备去泛素化酶（DUBs）抑制剂的方法。具体而言，本发明涉及抑制泛素C端水解酶L1（UCHL1）。本发明进一步涉及在癌症和其他适应症治疗中使用DUB抑制剂。本发明的化合物包括具有式（I）或其药用可接受盐的化合物，其中R1至R8如本文所定义。
• [EN] CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] DÉRIVÉS DE CARBOXAMIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN R & D IRELAND

  公开号：WO2015059212A1

  公开（公告）日：2015-04-30

  Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R1 to R7 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式(I)的HBV复制抑制剂包括立体化学同分异构体形式，以及其盐、水合物、溶剂合物，其中X，R1到R7的含义如本文所定义。本发明还涉及制备所述化合物的过程，含有它们的药物组合物以及它们在HBV疗法中的使用，单独或与其他HBV抑制剂结合使用。
• NOVEL PHARMACEUTICAL
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1987827A1

  公开（公告）日：2008-11-05

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X1 represents an optionally substituted carbon atom, X2 represents an optionally substituted carbon atom, an oxygen atom and the like, W1 represents a nitrogen atom and the like, Y11 represents a group represented by the formula CR2R3' (wherein R2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R3' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y21 represents a group represented by the formula CR4R5' (wherein R4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R5' represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R1 represents an electron-withdrawing group, and the formula - - - represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物，包含一种组分，该组分的结构式如下：其中，环A代表一个可选取代的5-至8环，环B代表一个可选进一步取代的4-至10环，环C代表一个可选进一步取代的苯环，X1代表一个可选取代的碳原子，X2代表一个可选取代的碳原子、氧原子等，W1代表一个氮原子等，Y11代表一个由式CR2R3'（其中，R2代表氢原子、氰基、硝基等，R3'分别代表键、氢原子、氰基、硝基等）表示的基团，Y21代表一个由式CR4R5'（其中，R4代表氢原子、氰基、硝基等，R5'分别代表键、氢原子、氰基、硝基等）表示的基团等，R1代表一个电子吸引基团，而式- - -表示单键或双键，或其盐或前药。
• Novel Pharmaceutical
  申请人：Yamaoka Masuo

  公开号：US20090042857A1

  公开（公告）日：2009-02-12

  A tissue-selective androgen receptor modulator containing a compound represented by the formula wherein Ring A represents an optionally substituted 5- to 8-membered ring, Ring B represents an optionally further substituted 4- to 10-membered ring, Ring C represents an optionally further substituted benzene ring, X 1 represents an optionally substituted carbon atom, X 2 represents an optionally substituted carbon atom, an oxygen atom and the like, W 1 represents a nitrogen atom and the like, Y 11 represents a group represented by the formula CR 2 R 3′ (wherein R 2 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 3′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively), Y 21 represents a group represented by the formula CR 4 R 5′ (wherein R 4 represents a hydrogen atom, a cyano group, a nitro group and the like, and R 5′ represents a bond, a hydrogen atom, a cyano group, a nitro group and the like, respectively) and the like, R 1 represents an electron-withdrawing group, and the formula represents a single bond or a double bond, or a salt thereof or a prodrug thereof.

  一种组合物的组成式，该组合物是一种组织选择性的雄激素受体调节剂，其中环A代表可选取代的5-至8-环，环B代表可选取代的4-至10-环，环C代表可选取代的苯环，X1代表可选取代的碳原子，X2代表可选取代的碳原子、氧原子等，W1代表氮原子等，Y11代表由式CR2R3'（其中R2代表氢原子、氰基、硝基等，R3'代表键、氢原子、氰基、硝基等，分别）表示的基团，Y21代表由式CR4R5'（其中R4代表氢原子、氰基、硝基等，R5'代表键、氢原子、氰基、硝基等，分别）表示的基团等，R1代表电子吸引基团，式表示单键或双键，或其盐或前药。
• CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：US20160264522A1

  公开（公告）日：2016-09-15

  Inhibitors of HBV replication of formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein X, R 1 to R 7 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  公式（I）的乙型肝炎病毒复制抑制剂，包括立体化学异构体形式，以及其盐类、水合物、溶剂化物，其中X，R1到R7的含义如本文所定义。本发明还涉及制备所述化合物的方法，包含它们的制药组合物以及它们在乙型肝炎病毒治疗中的使用，单独使用或与其他乙型肝炎病毒抑制剂联合使用。